critic
ill
patient
admit
intens
care
unit
icu
due
multipl
reason
among
medic
condit
communityacquir
respiratori
infect
frequent
reason
ventilatori
support
icu
communityacquir
pneumonia
cap
sever
form
includ
need
invas
mechan
ventil
andor
vasopressor
associ
high
mortal
rate
common
etiolog
bacteri
streptococcu
pneumonia
caus
almost
half
episod
cap
etiolog
identifi
howev
pandem
occur
influenza
number
case
admit
icu
viral
infect
rise
patient
etiolog
would
identifi
past
test
sensit
viral
molecular
diagnost
tool
addit
patient
current
admit
icu
preexist
medic
condit
predispos
viral
infect
studi
aim
analyz
current
evid
find
associ
influenza
also
emerg
often
opportunist
viral
infect
name
herp
simplex
viru
type
epsteinbarr
viru
ebv
cytomegaloviru
cmv
influenza
virus
belong
orthomyxoviru
famili
classifi
influenza
b
c
base
core
protein
envelop
influenza
viru
contain
two
major
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
ha
respons
cell
attach
membran
fusion
na
enabl
releas
new
virion
cell
cleav
bond
ha
sialic
acid
also
role
viral
ingress
cleav
sialyl
mucin
allow
viru
penetr
mucou
layer
influenza
virus
subclassifi
base
ha
na
glycoprotein
world
health
organ
nomenclatur
classif
influenza
viru
consist
follow
two
part
type
strain
design
influenza
virus
descript
antigen
specif
surfac
antigen
h
n
current
subtyp
ha
h
subtyp
na
n
mostli
circul
wild
bird
three
combin
known
circul
wide
human
influenza
b
viru
first
isol
circul
sole
human
anim
reservoir
minor
chang
protein
structur
influenza
viru
known
antigen
drift
mutat
allow
viru
evad
immun
system
caus
outbreak
influenza
antigen
drift
occur
influenza
b
c
virus
segment
genom
influenza
viru
genom
allow
exchang
entir
gene
segment
event
two
differ
influenza
virus
simultan
infect
replic
host
cell
antigen
shift
caus
reassort
two
differ
subtyp
influenza
viru
anim
human
subtyp
caus
phenotyp
chang
antigen
shift
occur
influenza
viru
infect
human
antigen
shift
result
epidem
pandem
pandem
strain
deriv
genet
reassort
human
avian
virus
epidem
occur
annual
accord
result
estim
million
case
seriou
ill
approxim
death
per
year
three
influenza
viru
pandem
centuri
one
pandem
centuri
influenza
pandem
catastroph
record
histori
estim
onethird
world
popul
million
peopl
infect
viru
total
death
estim
around
million
howev
acknowledg
death
toll
may
significantli
higher
may
fact
reach
million
influenza
virus
human
origin
bird
swine
first
human
influenza
viru
isol
design
circul
replac
subtyp
asian
influenza
hong
kong
viru
appear
asian
strain
longer
detect
human
viru
reappear
like
escap
laboratori
virus
along
influenza
b
virus
continu
cocircul
human
popul
undergo
consider
evolut
antigen
drift
influenza
virion
recogn
potenti
host
cell
detect
sialic
acid
bind
use
ha
viral
glycoprotein
sialic
nacetylneuramin
acid
found
nearli
anim
cell
form
either
linkag
configur
recogn
ha
protein
linkag
major
sialic
acid
found
gastrointestin
tract
duck
contrast
major
sialic
acid
found
upper
respiratori
epitheli
cell
human
contain
linkag
reason
avian
strain
easili
infect
human
exampl
order
avian
influenza
infect
human
must
penetr
deep
alveoli
receptor
viru
attach
host
cell
enter
cell
receptormedi
endocytosi
envelop
fuse
host
cell
protein
target
amantadin
form
ion
channel
allow
entri
ribonucleoprotein
necessari
viral
uncoat
replic
initi
respons
infect
character
proinflammatori
state
cell
activ
releas
proinflammatori
cytokin
tumor
necrosi
interleukin
il
secondari
phase
infect
character
antiinflammatori
state
state
activ
cell
secret
cytokin
state
depress
immun
activ
lead
secondari
infect
bacteri
coinfect
cmv
reactiv
influenza
viru
develop
host
mechan
counteract
activ
major
antivir
cytokin
influenza
protein
antagon
inhibit
action
ifn
protein
inhibit
ifn
induct
viral
polymeras
inhibit
ifn
function
protein
prevent
tlr
induct
viral
infect
trigger
dysregul
immun
system
induc
massiv
cytokin
respons
cytokin
storm
caus
endotheli
damag
dysfunct
deregul
coagul
consequ
alter
microvascular
permeabl
tissu
edema
shock
sever
influenza
vascular
hyperperm
lead
acut
lung
injuri
multiorgan
failur
encephalopathi
differ
strain
influenza
elicit
differ
immun
respons
suggest
may
caus
higher
viral
load
hypercytokinemia
also
shown
viral
replic
confin
respiratori
tract
also
occur
intestin
influenza
acut
respiratori
diseas
character
full
form
sudden
onset
respiratori
system
symptom
high
fever
characterist
featur
influenza
b
common
caus
influenzalik
ill
ili
pathogen
influenza
c
parainfluenza
respiratori
syncyti
viru
rsv
mycoplasma
pneumonia
also
caus
differ
strain
found
elicit
differ
clinic
featur
influenza
infect
found
sever
b
term
fever
leukopenia
creactiv
protein
wherea
gastrointestin
symptom
seem
common
influenza
b
howev
anoth
studi
found
similar
clinic
manifest
outcom
among
adult
influenza
influenza
b
wie
et
al
describ
leukopenia
thrombocytopenia
found
occur
often
patient
influenza
b
howev
rate
hospit
hospit
length
stay
lo
found
higher
influenza
addit
proport
male
femal
elderli
popul
significantli
higher
patient
influenza
compar
influenza
b
viral
pneumonia
common
complic
influenza
infect
studi
look
risk
factor
develop
pneumonia
influenza
infect
among
adult
hospit
influenza
pneumonia
multivari
analysi
factor
associ
pneumonia
age
year
caucasian
race
nurs
home
resid
chronic
lung
diseas
immunosuppress
asthma
patient
pneumonia
significantli
like
requir
icu
admiss
vs
requir
invas
mechan
ventil
mv
vs
increas
risk
death
vs
influenzaassoci
pneumonia
may
either
primari
viral
influenza
pneumonia
secondari
bacteri
pneumonia
influenzabacteri
coinfect
patient
pneumonia
significantli
like
hospit
lo
greater
week
requir
icu
admiss
requir
mv
increas
risk
death
among
patient
viral
pneumonia
factor
independ
associ
poor
outcom
defin
icu
admiss
need
mv
death
includ
nurs
home
resid
chronic
lung
diseas
cardiovascular
diseas
renal
diseas
immunosuppress
note
older
age
found
protect
factor
among
patient
hospit
pneumonia
coleman
et
al
examin
risk
factor
seriou
outcom
associ
influenza
ill
highincom
countri
hic
versu
lowand
middleincom
countri
lmic
found
patient
like
suffer
sever
outcom
icu
admiss
andor
death
vulner
popul
affect
comorbid
malign
immunesuppress
condit
renal
cardiac
lung
diseas
includ
tuberculosi
anoth
import
risk
factor
pregnanc
pregnant
women
lmic
percent
increas
risk
sever
outcom
compar
patient
influenza
howev
increas
risk
pregnant
women
hic
similarli
patient
hiv
increas
risk
sever
outcom
hic
howev
increas
risk
lmic
coinfect
treatment
cap
tradit
focus
bacteri
etiolog
recent
research
indic
virus
may
involv
cap
rapid
diagnost
test
thu
vital
import
identifi
offend
pathogen
initi
target
treatment
prevent
inappropri
use
antibiot
systemat
review
metaanalys
found
respiratori
virus
detect
approxim
cap
patient
influenza
consist
common
viral
pathogen
identifi
trend
toward
lower
identif
viral
pathogen
studi
publish
oppos
studi
publish
studi
virus
commonli
identifi
european
adult
patient
cap
less
frequent
influenza
b
rhinoviru
coronaviru
parainfluenza
human
metapneumoviru
rsv
adenoviru
frequenc
bacteri
coinfect
patient
influenza
report
streptococcu
pneumonia
aureu
common
pathogen
account
identifi
coinfect
bacteria
respect
influenza
infect
associ
pneumococc
pneumonia
influenza
season
overal
addit
grabowska
et
al
found
case
invas
pneumococc
diseas
associ
influenza
per
year
per
influenza
season
sever
pathogen
nonfer
gramneg
bacilli
also
identifi
caus
coinfect
sever
reason
propens
bacteri
coinfect
complex
yet
fulli
explain
appear
organismspecif
interact
aureu
pneumonia
caus
higher
rate
infect
bacteria
recent
multicent
studi
martinloech
et
al
includ
almost
critic
ill
patient
shown
coinfect
occur
frequent
sinc
coinfect
like
occur
older
immunosuppress
patient
addit
coinfect
independ
risk
factor
icu
mortal
mortal
hospit
mortal
anoth
recent
multicent
studi
analyz
immunosuppress
patient
found
categori
infecti
etiolog
respiratori
failur
influenza
noninfluenza
influenza
plu
coinfect
noninfecti
associ
icu
hospit
mortal
spanish
group
report
first
case
invas
aspergillosi
ia
patient
admit
icu
due
influenza
infect
retrospect
multicent
cohort
studi
schauwvliegh
et
al
examin
incid
ia
patient
admit
icu
sever
influenza
found
ia
present
immunocompromis
patient
immunocompet
patient
incid
ia
almost
equal
patient
influenza
influenza
b
addit
compar
nonimmunocompromis
influenzaposit
patient
equal
number
nonimmunocompromis
influenzaneg
patient
sever
cap
found
influenza
independ
associ
invas
pulmonari
aspergillosi
data
use
na
inhibitor
nai
intens
care
patient
limit
metaanalysi
muthuri
et
al
show
earli
initi
day
symptom
onset
nai
treatment
versu
late
initi
treatment
commenc
day
symptom
onset
reduc
mortal
requir
ventilatori
support
reduc
incid
influenzarel
pneumonia
patient
influenza
found
among
critic
ill
patient
popul
nai
use
associ
reduct
mortal
compar
therapi
odd
ratio
confid
interv
ci
earli
use
nai
associ
reduct
mortal
compar
late
initi
treatment
ci
impact
earli
day
symptom
onset
versu
late
day
symptom
onset
administr
oseltamivir
also
examin
rodrigo
p
studi
signific
effect
earli
versu
late
oseltamivir
observ
influenza
influenza
b
concern
regard
absorpt
oseltamivir
critic
ill
patient
led
sever
studi
use
highdos
oseltamivir
standard
dose
mg
twice
daili
found
achiev
similar
plasma
level
critic
ill
patient
compar
ambulatori
patient
concentr
far
excess
concentr
requir
maxim
inhibit
na
activ
viru
highdos
oseltamivir
also
shown
achiev
similar
effect
standard
dose
oseltamivir
term
mortal
viral
rna
day
oseltamivir
standard
durat
therapi
ambulatori
patient
suggest
therapi
continu
patient
remain
critic
state
day
treatment
intraven
nai
peramivir
shown
effect
oral
oseltamivir
term
mortal
length
icu
stay
could
thu
consid
altern
unabl
take
oral
oseltamivir
potenti
treatment
investig
systemat
review
metaanalysi
mairjenkin
et
al
examin
studi
convalesc
plasma
treatment
sever
acut
respiratori
infect
viral
etiolog
includ
post
hoc
metaanalysi
pool
data
eight
compar
studi
two
studi
sarscov
sever
acut
respiratori
syndromecoronaviru
infect
two
influenza
infect
one
avian
influenza
infect
three
spanish
influenza
infect
result
metaanalysi
suggest
convalesc
plasma
may
impact
reduc
mortal
viral
load
patient
sever
acut
respiratori
infect
viral
etiolog
case
report
rapid
reduct
detect
viral
load
patient
influenza
treat
convalesc
plasma
without
signific
seriou
event
prospect
cohort
studi
conduct
pandem
includ
patient
sever
infect
requir
intens
care
twenti
patient
receiv
convalesc
plasma
mortal
treatment
group
significantli
lower
vs
p
respiratori
tract
viral
load
also
significantli
lower
treatment
group
differ
studi
tri
analyz
associ
role
adjuv
immunomodulatori
agent
treatment
sever
influenza
includ
corticosteroid
statin
macrolid
nonimmun
intraven
immunoglobulin
nacetylcystein
pamidron
nitazoxanid
chloroquin
antibodi
ifn
human
mesenchym
stromal
cell
mycophenol
acid
peroxisom
proliferatoractiv
receptor
agonist
nonsteroid
antiinflammatori
agent
mesalazin
role
plasmapheresi
hemoperfus
rescu
therapi
none
immunomodulatori
therapi
shown
benefit
acknowledg
evid
unclear
due
limit
publish
databas
random
control
trial
rct
critic
ill
patient
two
coadjuv
treatment
gather
attent
macrolid
corticosteroid
use
macrolid
analyz
larg
cohort
patient
use
propens
score
analysi
use
associ
benefit
critic
ill
patient
cochran
review
origin
publish
follow
updat
review
includ
studi
particip
found
corticosteroid
therapi
associ
increas
mortal
similar
increas
risk
mortal
seen
stratifi
analysi
studi
report
adjust
estim
associ
corticosteroid
therapi
increas
mortal
also
seen
pool
analysi
six
studi
report
adjust
hazard
ratio
hr
hr
ci
increas
odd
hospitalacquir
infect
relat
corticosteroid
therapi
found
pool
analysi
seven
studi
pool
ci
unadjust
estim
data
grade
low
certainti
limit
review
includ
inconsist
report
variabl
low
qualiti
data
specif
mortal
corticosteroid
shown
sever
metaanalys
associ
increas
mortal
caveat
suggest
corticosteroid
may
given
sicker
patient
studi
includ
metaanalys
patient
mortal
go
higher
anyway
author
metaanalys
also
conclud
lack
suffici
power
random
trial
examin
issu
regard
extracorpor
life
support
pandem
saw
increas
frequenc
use
venoven
extracorpor
membran
oxygen
ecmo
rescu
therapi
patient
sever
acut
respiratori
distress
syndrom
ard
systemat
review
sukhal
et
al
examin
use
ecmo
sever
influenza
infect
lack
random
trial
studi
result
suggest
benefit
initi
ecmo
sever
respiratori
failur
secondari
influenza
incid
myocard
patient
influenza
may
high
commonli
occur
day
onset
influenza
symptom
myocard
diagnos
base
combin
symptom
elev
cardiac
enzym
echocardiograph
find
myocard
limit
sever
respiratori
manifest
influenza
symptom
relat
myocard
chest
pain
dyspnea
syncop
may
caus
present
hospit
first
instanc
clinic
manifest
rang
subclin
myocard
sudden
death
newonset
atrial
ventricular
arrhythmia
complet
heart
block
heart
failur
pericardi
effus
cardiac
tamponad
acut
myocardi
infect
ami
like
syndrom
common
complic
congest
heart
failur
diagnos
global
hypokinesi
echomri
magnet
reson
imag
report
patient
influenzaassoci
myocard
major
myocarditisrel
reduc
eject
fraction
rang
experienc
resolut
systol
function
typic
within
day
onset
dysfunct
mani
patient
develop
influenzarel
myocard
requir
advanc
cardiac
support
therapi
intraaort
balloon
pump
ecmo
earli
diagnosi
paramount
mortal
report
approxim
import
note
reduc
eject
fraction
absenc
myocard
report
influenza
infect
right
ventricular
dysfunct
appear
common
left
ventricular
dysfunct
would
normal
expect
patient
ard
metaanalysi
casecontrol
studi
barn
et
al
found
recent
influenza
infect
ili
respiratori
tract
infect
significantli
like
ami
case
pool
ci
addit
influenza
vaccin
neg
associ
ami
pool
ci
find
keep
studi
associ
influenza
ami
influenza
vaccin
ami
pathogenesi
may
due
sever
mechan
includ
increas
coronari
system
inflammatori
activ
drive
procoagul
process
domin
prothrombot
condit
increas
biomechan
stress
coronari
arteri
variat
coronari
arteri
tone
disturb
hemodynam
hemostasi
alter
metabol
balanc
less
common
cardiovascular
complic
dysrhythmia
pericard
commonli
report
cardiac
arrhythmia
associ
influenza
atrioventricular
conduct
block
ventricular
fibril
usual
due
underli
fulmin
myocard
although
pericard
recogn
complic
influenza
infect
often
mild
uncompl
influenzaassoci
enceph
encephalopathi
syndrom
character
impair
level
conscious
occur
within
day
influenza
infect
common
neurolog
symptom
confus
seizur
mri
comput
tomographi
ct
commonli
produc
abnorm
find
lesion
locat
throughout
brain
characterist
pattern
area
focu
common
associ
agent
guillainbarr
syndrom
gb
campylobact
jejuni
pneumonia
ebv
case
gb
clear
etiolog
identifi
influenza
viru
propos
import
underrecogn
caus
gb
numer
studi
found
significantli
increas
risk
gb
month
follow
influenza
infect
addit
neurolog
complic
elev
creatin
kinas
ck
suggest
biomark
sever
influenza
infect
studi
borgatta
et
al
case
influenza
infect
ck
uil
associ
greater
renal
dysfunct
requir
renal
replac
therapi
increas
ck
uil
associ
greater
intub
risk
longer
durat
mv
extra
day
icu
hospit
lo
rhabdomyolysi
although
rare
report
associ
influenza
infect
hospit
fatal
risk
defin
probabl
death
among
patient
requir
hospit
medic
reason
examin
systemat
review
metaanalysi
wong
et
al
crude
estim
hfr
rang
howev
substanti
heterogen
studi
higher
estim
came
tertiarycar
referr
hospit
countri
lower
gross
domest
product
gdp
countri
lower
gdp
hypothes
higher
threshold
hospit
admiss
icu
treatment
hospit
case
may
sever
countri
higher
gdp
risk
death
would
thu
higher
wealthi
countri
estim
set
systemat
review
khandak
et
al
found
confirm
case
fatal
rate
hic
upperand
lowermiddl
incom
countri
pandem
mortal
rate
critic
ill
patient
sever
influenza
requir
admiss
icu
pandem
approxim
hic
uppermiddl
incom
countri
lowermiddl
incom
countri
immunoparalysi
follow
initi
proinflammatori
respons
physiolog
insult
sepsi
trauma
etc
frequent
nonimmunocompromis
icu
patient
one
consequ
immunoparalysi
reactiv
latent
virus
herpesvirida
mostli
hsv
cmv
ebv
frequent
numer
studi
evalu
hsv
reactiv
icu
patient
summar
studi
hsv
reactiv
start
oropharyng
tract
icu
patient
day
icu
admiss
follow
descend
lower
respiratori
tract
colon
mechan
ventil
patient
median
day
mv
peak
viru
load
day
mv
start
patient
true
lung
infect
hsv
bronchopneumon
occur
median
day
mv
studi
evalu
patient
prolong
day
mv
luyt
et
al
found
hsv
bronchopneumon
cytolog
andor
histolog
sign
deep
lung
infect
distinguish
hsv
lung
reactiv
infect
may
difficult
inde
lung
infect
defin
clinic
sign
presenc
hsv
cytologicalhistolog
criteria
hsvspecif
nuclear
inclus
cell
collect
bronchoalveolar
lavag
bal
howev
techniqu
difficult
implement
may
subject
viru
load
bal
fluid
cutoff
set
copiesml
may
good
altern
hsv
reactiv
associ
poor
outcom
metaanalysi
show
hsv
reactiv
associ
mortal
ci
howev
exact
signific
hsv
reactiv
ie
bystand
true
pathogen
morbiditymort
remain
determin
date
one
small
random
control
studi
use
prophylact
acyclovir
fail
demonstr
clinic
benefici
effect
antivir
treatment
one
retrospect
studi
found
improv
mortal
hsv
carrier
receiv
acyclovir
one
prospect
studi
fail
show
benefici
effect
acyclovir
patient
hsv
bronchopneumon
blood
andor
lung
cmv
reactiv
may
occur
icu
patient
blood
cmv
reactiv
occur
onethird
cmvseroposit
icu
patient
median
day
admiss
lung
cmv
reactivationinfect
less
frequent
occur
mechan
ventil
patient
frequenc
reach
patient
acut
lung
injuri
without
obviou
caus
recent
metaanalysi
show
icu
may
experi
cmv
reactiv
whatev
site
blood
lung
reactiv
although
cmv
blood
reactiv
associ
poor
prognosi
studi
evalu
relationship
cmv
blood
reactiv
cmv
diseas
ie
organ
involv
cmv
lung
diseas
almost
exclus
diagnos
use
histolog
lung
biopsi
autopsi
wherea
use
cytolog
balcollect
cell
look
cmvspecif
inclus
quantit
polymeras
chain
reaction
pcr
never
investig
like
hsv
cmv
reactiv
associ
poor
outcom
recent
metaanalysi
show
cmv
reactiv
nonimmunocompromis
patient
associ
mortal
ci
moreov
limay
et
al
found
cmv
viru
load
associ
mortal
higher
viru
load
higher
mortal
howev
exact
signific
cmv
reactiv
known
could
marker
sever
bystand
pathogen
true
morbid
andor
mortal
two
random
control
trial
evalu
effect
prophylact
anticmv
treatment
cmvposit
icu
patient
recent
publish
first
one
evalu
prophylact
valganciclovir
valacyclovir
compar
placebo
decreas
cmv
reactiv
inclus
valacyclovir
arm
prematur
stop
due
unexplain
increas
mortal
patient
treat
valganciclovir
less
cmv
reactiv
similar
outcom
placebotr
patient
second
one
doubleblind
placebocontrol
trial
author
evalu
prophylact
ganciclovir
reduc
level
measur
day
random
although
ganciclovir
fail
reduc
level
day
compar
placebo
trend
toward
increas
ventilatorfre
day
day
patient
receiv
ganciclovir
similar
mortal
recent
author
investig
frequenc
ebv
dna
detect
bal
fluid
blood
use
pcr
found
ebv
dna
detect
frequent
icu
patient
seem
associ
mortal
exact
signific
ebv
detect
icu
patient
determin
thu
consid
specif
treatment
ebv
icu
patient
ebv
dna
detect
date
prematur
summari
herpesvirida
reactiv
frequent
icu
patient
associ
mortal
howev
exact
signific
herpesvirida
reactiv
poorli
understood
case
associ
true
diseas
case
relationship
viral
reactiv
viral
diseas
establish
latter
case
wherea
specif
antivir
treatment
may
improv
outcom
remain
determin
date
neither
prophylact
acyclovir
prevent
hsv
reactiv
prophylact
ganciclovir
prevent
cmv
reactiv
recommend
preemptiv
treatment
acyclovir
patient
oropharyng
hsv
reactiv
ganciclovir
patient
cmv
blood
reactiv
investig
pth
preemptiv
treatment
herpesvirida
studi
clinic
trial
cur
treatment
hsv
bronchopneumon
cmv
lung
diseas
base
expert
opinion
patient
either
cytologicalhistolog
proof
lung
involv
high
viral
load
specif
clinic
biolog
pattern
suggest
cmv
summari
patient
icu
risk
viral
infect
immunocompet
patient
common
viral
infect
respiratori
influenza
consid
patient
sever
respiratori
failur
admit
icu
season
coinfect
two
import
featur
consid
influenza
pathogen
critic
ill
patient
viral
infect
frequent
immunosuppress
patient
solid
organ
hematopoiet
stem
cell
transplant
recipi
well
receiv
chemotherapi
malign
hematolog
diseas
clearli
predispos
varieti
viral
infect
common
opportunist
patient
may
acquir
infect
commun
donor
organ
donorderiv
infect
andor
reactiv
endogen
latent
viru
hsv
especi
cmv
ebv
among
common
opportunist
viral
pathogen
affect
patient
addit
respiratori
virus
recent
year
sever
studi
found
opportunist
infect
also
caus
develop
infect
immunocompet
patient
transient
degre
induc
immunosuppress
